Longeveron (LGVN) EBT Margin Growth (1y) (2021 - 2026)
Longeveron (LGVN) EBT Margin Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBT Margin Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
-1,532.00 |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
1,558.00 |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Longeveron |
20.35 Bn |
20.33 Bn |
264,000.00 |
16,009.00 |
| Date | Value |
|---|
| Mar 31, 2026 |
16,009.00 |
| Dec 31, 2025 |
-76,923.00 |
| Sep 30, 2025 |
-473,434.00 |
| Jun 30, 2025 |
-96,005.00 |
| Mar 31, 2025 |
-61,349.00 |
| Dec 31, 2024 |
792,497.00 |
| Sep 30, 2024 |
283,924.00 |
| Jun 30, 2024 |
188,439.00 |
| Mar 31, 2024 |
94,397.00 |
| Dec 31, 2023 |
-314,897.00 |
| Sep 30, 2023 |
174,633.00 |
| Jun 30, 2023 |
-172,646.00 |
| Mar 31, 2023 |
-77,303.00 |
| Dec 31, 2022 |
-355,629.00 |
| Sep 30, 2022 |
-307,234.00 |
| Jun 30, 2022 |
12,979.00 |
| Mar 31, 2022 |
238.00 |
| Dec 31, 2021 |
-190,366.00 |
| Sep 30, 2021 |
-206,307.00 |
| Jun 30, 2021 |
-62,692.00 |
